A decade of genome-wide gene expression profiling in acute myeloid leukemia: Flashback and prospects
The past decade has shown a marked increase in the use of high-throughput assays in clinical research into human cancer, including acute myeloid leukemia (AML). In particular, genome-wide gene expression profiling (GEP) using DNA microarrays has been extensively used for improved understanding of the diagnosis, prognosis, and pathobiology of this heterogeneous disease. This review discusses the progress that has been made, places the technologic limitations in perspective, and highlights promising future avenues.
|Persistent URL||dx.doi.org/10.1182/blood-2008-04-153239, hdl.handle.net/1765/27240|
Wouters, B.J, Löwenberg, B, & Delwel, H.R. (2009). A decade of genome-wide gene expression profiling in acute myeloid leukemia: Flashback and prospects. Blood, 113(2), 291–298. doi:10.1182/blood-2008-04-153239